"GTAEXS617 is a product of our collaboration that uses AI-driven precision design to create a potentially best-in-class therapy and provide a new therapeutic option for patients with these difficult to treat cancers." "The initiation of the ELUCIDATE study represents a significant milestone in our company’s development and is the first drug candidate from our partnership with Exscientia to enter clinical studies," said Mingxi Li, Ph.D., chief executive officer of GT Apeiron. The ELUCIDATE trial is designed to evaluate the safety, efficacy, and pharmacokinetics of GTAEXS617 across multiple ascending doses, as a monotherapy and in combination with standard of care therapy, in adults with advanced solid tumors. Developed in collaboration with its strategic partner, Exscientia plc (Nasdaq: EXAI), GTAEXS617 is a highly selective, small molecule, non-covalent inhibitor of cyclin-dependent kinase 7 (CDK7). ![]() SAN FRANCISCO and SHANGHAI, China, J(GLOBE NEWSWIRE) - GT Apeiron, a biopharmaceutical company harnessing the power of artificial intelligence (AI) to develop targeted precision therapies for unmet medical needs, today announced the enrollment of the first patient in the Phase 1/2 “ELUCIDATE” study which is designed to evaluate GTAEXS617 for the treatment of advanced solid tumors. Parallel translational initiative to evaluate preclinically identified non-invasive PD biomarkers with potential to predict GTAEXS617 treatment responders. ![]() Preclinical data from AI-optimized GTAEXS617 support potential for improved therapeutic index compared to other CDK7 inhibitors under development.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |